{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:26:09Z","timestamp":1777973169804,"version":"3.51.4"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.rdc.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:56:12Z","timestamp":1536296172000},"page":"525-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Renal Involvement in Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis"],"prefix":"10.1016","volume":"44","author":[{"given":"Reza","family":"Zonozi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Niles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank B.","family":"Cortazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.rdc.2010.05.002","article-title":"Pauci-immune necrotizing glomerulonephritis","volume":"36","author":"Rutgers","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.med.47.1.303","article-title":"Antineutrophil cytoplasmic antibodies in the classification of vasculitis","volume":"47","author":"Niles","year":"1996","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","article-title":"Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients","volume":"42","author":"Guillevin","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.001_bib4","doi-asserted-by":"crossref","first-page":"643.e9-14","DOI":"10.1016\/j.amjmed.2006.08.016","article-title":"ANCA are detectable in nearly all patients with active severe Wegener\u2019s granulomatosis","volume":"120","author":"Finkielman","year":"2007","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1523-1755.2002.00089.x","article-title":"Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups","volume":"61","author":"Hauer","year":"2002","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.001_bib6","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/art.21250","article-title":"Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome","volume":"52","author":"Sinico","year":"2005","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","article-title":"Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients","volume":"78","author":"Guillevin","year":"1999","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.rdc.2010.04.002","article-title":"Epidemiology of ANCA-associated vasculitis","volume":"36","author":"Ntatsaki","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.001_bib10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody\u2013associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.001_bib11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.rmed.2013.01.006","article-title":"Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis","volume":"107","author":"Ando","year":"2013","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5","article-title":"Drug-associated antineutrophil cytoplasmic antibody\u2013positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies","volume":"43","author":"Choi","year":"2000","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/art.40034","article-title":"Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody\u2013associated vasculitis","volume":"69","author":"Merkel","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/BOR.0000000000000014","article-title":"Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis","volume":"26","author":"Pendergraft","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.001_bib15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrneph.2012.108","article-title":"Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis","volume":"8","author":"Chen","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.001_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3109\/08860220903118590","article-title":"Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review","volume":"31","author":"Dobre","year":"2009","journal-title":"Ren Fail"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.001_bib17","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.2215\/CJN.03440411","article-title":"Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease","volume":"6","author":"McGrath","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.001_bib18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.001_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.ajkd.2005.01.001","article-title":"Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs","volume":"45","author":"Schlieben","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1523-1755.2005.00431.x","article-title":"Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils","volume":"68","author":"Van Rossum","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.001_bib22","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in\u00a0vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib23","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4049\/jimmunol.153.3.1271","article-title":"Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa","volume":"153","author":"Porges","year":"1994","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1681\/ASN.V83386","article-title":"Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils","volume":"8","author":"Kettritz","year":"1997","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.001_bib26","doi-asserted-by":"crossref","first-page":"e0158871","DOI":"10.1371\/journal.pone.0158871","article-title":"Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis","volume":"11","author":"Augusto","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.001_bib28","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib29","first-page":"921","article-title":"Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis","volume":"135","author":"Jennette","year":"1989","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.001_bib30","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1111\/j.1523-1755.2004.00632.x","article-title":"Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases","volume":"65","author":"Haas","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/ndt\/18.3.524","article-title":"Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis","volume":"18","author":"Neumann","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/ki.1987.67","article-title":"The existence of a protracted course in crescentic glomerulonephritis","volume":"31","author":"Baldwin","year":"1987","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ki.1995.23","article-title":"Differences between anti-myeloperoxidase-and anti-proteinase 3-associated renal disease","volume":"47","author":"Franssen","year":"1995","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.001_bib35","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.001_bib36","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1681\/ASN.2010090928","article-title":"Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease","volume":"22","author":"Olson","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.04060808","article-title":"Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis","volume":"4","author":"Nasr","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/ndt\/12.5.1017","article-title":"Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases","volume":"12","author":"Tse","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.001_bib40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1191\/0961203303lu456rr","article-title":"Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus","volume":"12","author":"Sen","year":"2003","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0272-6386(12)80171-5","article-title":"The pathology of vasculitis involving the kidney","volume":"24","author":"Jennette","year":"1994","journal-title":"Am J kidney Dis"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib42","first-page":"185","article-title":"Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener's granulomatosis","volume":"33","author":"Bir","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.001_bib43","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/ard.59.11.898","article-title":"Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis","volume":"59","author":"Locht","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1681\/ASN.V2127","article-title":"Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis","volume":"2","author":"Niles","year":"1991","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0046-8177(93)90295-R","article-title":"Correlation of antineutrophil cytoplasmic antibodies with the extrarenal histopathology of Wegener's (pathergic) granulomatosis and related forms of vasculitis","volume":"24","author":"Fienberg","year":"1993","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.001_bib46","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/0003-4819-126-11-199706010-00003","article-title":"Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease","volume":"126","author":"Merkel","year":"1997","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib47","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/ki.1998.36","article-title":"Diagnostic predictive value of ANCA serology","volume":"53","author":"Jennette","year":"1998","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.001_bib48","first-page":"1584","article-title":"Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies","volume":"28","author":"Choi","year":"2001","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.001_bib49","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.001_bib51","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody\u2014associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.001_bib52","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.001_bib53","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3899\/jrheum.150065","article-title":"Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases","volume":"42","author":"Yilmaz","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.001_bib54","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.001_bib55","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib56","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"issue":"25","key":"10.1016\/j.rdc.2018.06.001_bib57","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.001_bib58","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A\u00a0multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.001_bib59","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody\u2013associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am J Med"},{"issue":"3\u20134","key":"10.1016\/j.rdc.2018.06.001_bib61","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000368569","article-title":"Limitations of standard immunosuppressive treatment in ANCA-associated vasculitis and lupus nephritis","volume":"128","author":"Tesar","year":"2014","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.001_bib62","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am J kidney Dis"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.001_bib63","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.rdc.2018.06.001_bib67","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody\u2013associated vasculitis: A randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.rdc.2018.06.001_bib68","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.001_bib69","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"10.1016\/j.rdc.2018.06.001_bib70","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar1957","article-title":"Anti-inflammatory and immunosuppressive drugs and reproduction","volume":"8","author":"\u00d8stensen","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2018.06.001_bib72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ard.41.Suppl_1.44","article-title":"Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities","volume":"41","author":"Whisnant","year":"1982","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jdv.12041","article-title":"Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases","volume":"28","author":"Van den Reek","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib74","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2018.06.001_bib75","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J\u00a0Autoimmun"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.001_bib76","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib77","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.001_bib78","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.001_bib79","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","article-title":"Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody\u2013associated small-vessel vasculitis: comparison of two independent cohorts","volume":"58","author":"Pagnoux","year":"2008","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib80","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0000000000000020","article-title":"Granulomatosis with polyangiitis (Wegener\u2019s): impact of maintenance therapy duration","volume":"93","author":"Springer","year":"2014","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.001_bib81","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ki.2009.218","article-title":"The clinical course of ANCA small-vessel vasculitis on chronic dialysis","volume":"76","author":"Lionaki","year":"2009","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib82","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.001_bib83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/BOR.0000000000000006","article-title":"Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"26","author":"Moran","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.001_bib84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.001_bib85","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1503\/cmaj.1041588","article-title":"Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation","volume":"173","author":"Knoll","year":"2005","journal-title":"Can Med Assoc J"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.001_bib86","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1046\/j.1523-1755.1999.00666.x","article-title":"Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis","volume":"56","author":"Nachman","year":"1999","journal-title":"Kidney Int"},{"issue":"suppl_1","key":"10.1016\/j.rdc.2018.06.001_bib87","first-page":"i159","article-title":"Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"30","author":"Hruskova","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.001_bib88","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/TP.0b013e31821ab9aa","article-title":"Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience","volume":"91","author":"Geetha","year":"2011","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.001_bib89","first-page":"139","article-title":"Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"Cattran","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.001_bib90","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/ndt\/gfr127","article-title":"Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis","volume":"26","author":"Mansfield","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.001_bib91","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfy075","article-title":"Long-term follow-up of a\u00a0combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"33","author":"McAdoo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.001_bib92","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:17:26Z","timestamp":1760181446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X18300541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0889857X18300541"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2018.06.001","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Involvement in Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}